|
AU1941501A
(en)
*
|
1999-11-30 |
2001-06-12 |
Parker Hughes Institute |
Syk localized at centrosome
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
US20040171062A1
(en)
*
|
2002-02-28 |
2004-09-02 |
Plexxikon, Inc. |
Methods for the design of molecular scaffolds and ligands
|
|
CN103169708B
(zh)
|
2002-07-29 |
2018-02-02 |
里格尔药品股份有限公司 |
用2,4‑嘧啶二胺化合物治疗或者预防自体免疫性疾病的方法
|
|
US20040142864A1
(en)
*
|
2002-09-16 |
2004-07-22 |
Plexxikon, Inc. |
Crystal structure of PIM-1 kinase
|
|
US20050282814A1
(en)
*
|
2002-10-03 |
2005-12-22 |
Targegen, Inc. |
Vasculostatic agents and methods of use thereof
|
|
US7456190B2
(en)
*
|
2003-03-13 |
2008-11-25 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as protein kinase inhibitors
|
|
US20050014753A1
(en)
*
|
2003-04-04 |
2005-01-20 |
Irm Llc |
Novel compounds and compositions as protein kinase inhibitors
|
|
JP2007516196A
(ja)
*
|
2003-07-02 |
2007-06-21 |
ガラパゴス エヌブイ |
Ｒｈｏキナーゼ阻害剤としてのピラジン及びピラリジン誘導体
|
|
WO2005012262A1
(en)
|
2003-07-30 |
2005-02-10 |
Cyclacel Limited |
2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
|
|
US7122542B2
(en)
|
2003-07-30 |
2006-10-17 |
Rigel Pharmaceuticals, Inc. |
Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds
|
|
EP1694686A1
(en)
*
|
2003-12-19 |
2006-08-30 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
NZ551027A
(en)
*
|
2004-04-08 |
2011-01-28 |
Targegen Inc |
Benzotriazine inhibitors of kinases
|
|
WO2005105788A1
(en)
*
|
2004-04-23 |
2005-11-10 |
Takeda San Diego, Inc. |
Indole derivatives and use thereof as kinase inhibitors
|
|
EP1751133B1
(en)
|
2004-04-28 |
2010-04-14 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of rock and other protein kinases
|
|
PL3305776T3
(pl)
|
2004-05-14 |
2020-03-31 |
Vertex Pharmaceuticals Incorporated |
Związki pirolowe jako inhibitory kinaz białkowych erk i kompozycje farmaceutyczne zawierające te związki
|
|
JP2008510734A
(ja)
*
|
2004-08-18 |
2008-04-10 |
タケダ サン ディエゴ インコーポレイテッド |
キナーゼ阻害剤
|
|
JP5275628B2
(ja)
|
2004-08-25 |
2013-08-28 |
ターゲジェン インコーポレーティッド |
複素環式化合物および使用方法
|
|
US8771754B2
(en)
*
|
2004-09-17 |
2014-07-08 |
Vanderbilt University |
Use of GSK3 inhibitors in combination with radiation therapies
|
|
EP1812439B2
(en)
|
2004-10-15 |
2017-12-06 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
US7968574B2
(en)
*
|
2004-12-28 |
2011-06-28 |
Kinex Pharmaceuticals, Llc |
Biaryl compositions and methods for modulating a kinase cascade
|
|
US7449458B2
(en)
|
2005-01-19 |
2008-11-11 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
AU2006219231B2
(en)
|
2005-02-28 |
2010-01-14 |
Japan Tobacco Inc. |
Novel aminopyridine compound with Syk inhibitory activity
|
|
RU2485106C2
(ru)
|
2005-06-08 |
2013-06-20 |
Райджел Фамэсьютикэлз, Инк. |
Соединения, проявляющие активность в отношении jak-киназы (варианты), способ лечения заболеваний, опосредованных jak-киназой, способ ингибирования активности jak-киназы (варианты), фармацевтическая композиция на основе указанных соединений
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
AU2006254825A1
(en)
*
|
2005-06-08 |
2006-12-14 |
Targegen, Inc. |
Methods and compositions for the treatment of ocular disorders
|
|
US20060281788A1
(en)
|
2005-06-10 |
2006-12-14 |
Baumann Christian A |
Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
|
|
US8071768B2
(en)
|
2005-06-10 |
2011-12-06 |
Janssen Pharmaceutica, N.V. |
Alkylquinoline and alkylquinazoline kinase modulators
|
|
US7825244B2
(en)
|
2005-06-10 |
2010-11-02 |
Janssen Pharmaceutica Nv |
Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
|
|
US7576053B2
(en)
|
2005-06-13 |
2009-08-18 |
Rigel Pharmaceuticals, Inc. |
Methods and compositions for treating degenerative bone disorders
|
|
PT1734251E
(pt)
*
|
2005-06-17 |
2007-03-30 |
Magneti Marelli Powertrain Spa |
Injector de combustível
|
|
EP1907347A2
(en)
*
|
2005-07-12 |
2008-04-09 |
Arcadia Pharmaceuticals Inc. |
Compounds with activity at retinoic acid receptors
|
|
US8211919B2
(en)
*
|
2005-09-02 |
2012-07-03 |
Astellas Pharma Inc. |
Amide derivatives as rock inhibitors
|
|
US7512864B2
(en)
*
|
2005-09-30 |
2009-03-31 |
Josef Zeevi |
System and method of accessing non-volatile computer memory
|
|
US8119655B2
(en)
*
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
EA200801118A1
(ru)
|
2005-10-18 |
2008-10-30 |
Янссен Фармацевтика Н.В. |
Способ ингибирования flt3 киназы
|
|
US8133900B2
(en)
*
|
2005-11-01 |
2012-03-13 |
Targegen, Inc. |
Use of bi-aryl meta-pyrimidine inhibitors of kinases
|
|
US8604042B2
(en)
*
|
2005-11-01 |
2013-12-10 |
Targegen, Inc. |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
MY167260A
(en)
*
|
2005-11-01 |
2018-08-14 |
Targegen Inc |
Bi-aryl meta-pyrimidine inhibitors of kinases
|
|
WO2007056023A2
(en)
*
|
2005-11-02 |
2007-05-18 |
Targegen, Inc. |
Thiazole inhibitors targeting resistant kinase mutations
|
|
EP1979329A2
(en)
*
|
2006-01-30 |
2008-10-15 |
Exelixis, Inc. |
4-aryl-2-amino-pyrimidines or 4-aryl-2-aminoalkyl-pyrimidines as jak-2 modulators and methods of use
|
|
US8962643B2
(en)
|
2006-02-24 |
2015-02-24 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
|
US7834178B2
(en)
*
|
2006-03-01 |
2010-11-16 |
Bristol-Myers Squibb Company |
Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
|
|
JP5137818B2
(ja)
|
2006-03-20 |
2013-02-06 |
生化学工業株式会社 |
関節リウマチの処置剤
|
|
MX2008012479A
(es)
|
2006-03-29 |
2009-08-13 |
Velacor Therapeutics Pty Ltd |
Tratamiento de enfermedades neurodegenerativas.
|
|
US8697716B2
(en)
|
2006-04-20 |
2014-04-15 |
Janssen Pharmaceutica Nv |
Method of inhibiting C-KIT kinase
|
|
PL2021335T3
(pl)
|
2006-04-20 |
2011-10-31 |
Janssen Pharmaceutica Nv |
Związki heterocykliczne jako inhibitory kinazy C-FMS
|
|
WO2007124322A1
(en)
|
2006-04-20 |
2007-11-01 |
Janssen Pharmaceutica N.V. |
Inhibitors of c-fms kinase
|
|
JP5564251B2
(ja)
|
2006-06-29 |
2014-07-30 |
キネックス ファーマシューティカルズ， エルエルシー |
キナーゼカスケードを調節するためのビアリール組成物および方法
|
|
WO2008008234A1
(en)
|
2006-07-07 |
2008-01-17 |
Targegen, Inc. |
2-amino-5-substituted pyrimidine inhibitors
|
|
EP2223925A1
(en)
*
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
JP2010505962A
(ja)
|
2006-10-09 |
2010-02-25 |
武田薬品工業株式会社 |
キナーゼ阻害剤
|
|
US20080153822A1
(en)
*
|
2006-11-30 |
2008-06-26 |
Martin Augustin |
Methods of treating pain
|
|
US7935697B2
(en)
|
2006-12-28 |
2011-05-03 |
Kinex Pharmaceuticals, Llc |
Compositions for modulating a kinase cascade and methods of use thereof
|
|
HUE029188T2
(en)
|
2007-03-12 |
2017-03-28 |
Ym Biosciences Australia Pty |
Phenylamino-pyrimidine compounds and their use
|
|
WO2008119109A1
(en)
|
2007-03-29 |
2008-10-09 |
Velacor Therapeutics Pty Ltd |
Treatment of neurological disorders
|
|
EP2193119B1
(en)
*
|
2007-08-27 |
2014-01-01 |
Abbvie Deutschland GmbH & Co. KG |
4-(4-pyridinyl)-benzamides and their use as rock activity modulators
|
|
JO3240B1
(ar)
|
2007-10-17 |
2018-03-08 |
Janssen Pharmaceutica Nv |
c-fms مثبطات كيناز
|
|
HRP20170317T1
(hr)
|
2008-02-15 |
2017-04-21 |
Rigel Pharmaceuticals, Inc. |
Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
|
|
US20110189308A1
(en)
*
|
2008-03-17 |
2011-08-04 |
Asa Abeliovich |
Methods to treat neurodegenerative conditions or diseases by targeting components of a pten signaling pathway
|
|
US8138339B2
(en)
|
2008-04-16 |
2012-03-20 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
PT2323993E
(pt)
|
2008-04-16 |
2015-10-12 |
Portola Pharm Inc |
2,6-diamino-pirimidina-5-il-carboxamidas como inibidores de quinasses syk ou jak
|
|
US8258144B2
(en)
|
2008-04-22 |
2012-09-04 |
Portola Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
CN102099491A
(zh)
*
|
2008-05-15 |
2011-06-15 |
北卡罗来纳-查佩尔山大学 |
调节血管生成的新靶标
|
|
US8263547B2
(en)
|
2008-05-28 |
2012-09-11 |
Massachusetts Institute Of Technology |
DISC-1 pathway activators in the control of neurogenesis
|
|
WO2010068863A2
(en)
|
2008-12-12 |
2010-06-17 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
|
KR20120016247A
(ko)
*
|
2009-05-19 |
2012-02-23 |
다우 아그로사이언시즈 엘엘씨 |
진균 방제를 위한 화합물 및 방법
|
|
KR101790255B1
(ko)
|
2009-12-23 |
2017-10-26 |
다케다 야쿠힌 고교 가부시키가이샤 |
Ｓｙｋ 억제제로서의 융합된 헤테로방향족 피롤리디논
|
|
HUE045270T2
(hu)
|
2010-01-05 |
2019-12-30 |
Inst Nat Sante Rech Med |
FLT3 receptor anatgonisták fájdalom rendellenességek kezelésére
|
|
AU2011206621B2
(en)
|
2010-01-12 |
2016-04-14 |
Ab Science |
Thiazole and oxazole kinase inhibitors
|
|
US8334292B1
(en)
|
2010-06-14 |
2012-12-18 |
Cystic Fibrosis Foundation Therapeutics, Inc. |
Pyrimidine compounds and methods of making and using same
|
|
DK2621945T3
(en)
*
|
2010-09-28 |
2018-05-22 |
Nono Inc |
ND2 PEPTIDES AND METHODS OF TREATING NEUROLOGICAL DISEASE
|
|
EP2975027A1
(en)
|
2010-11-01 |
2016-01-20 |
Portola Pharmaceuticals, Inc. |
Nicotinamides as jak kinase modulators
|
|
WO2012060847A1
(en)
|
2010-11-07 |
2012-05-10 |
Targegen, Inc. |
Compositions and methods for treating myelofibrosis
|
|
WO2012062704A1
(en)
*
|
2010-11-09 |
2012-05-18 |
Cellzome Limited |
Pyridine compounds and aza analogues thereof as tyk2 inhibitors
|
|
WO2012112933A1
(en)
|
2011-02-18 |
2012-08-23 |
The Scripps Research Institute |
Directed differentiation of oligodendrocyte precursor cells to a myelinating cell fate
|
|
EP2723739B1
(en)
|
2011-06-22 |
2016-08-24 |
Takeda Pharmaceutical Company Limited |
Substituted 6-aza-isoindolin-1-one derivatives
|
|
DE102011112978A1
(de)
*
|
2011-09-09 |
2013-03-14 |
Merck Patent Gmbh |
Benzonitrilderivate
|
|
US8877760B2
(en)
|
2011-11-23 |
2014-11-04 |
Portola Pharmaceuticals, Inc. |
Substituted pyrazine-2-carboxamide kinase inhibitors
|
|
EP2841428B1
(en)
|
2012-04-24 |
2018-08-22 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
|
US8809359B2
(en)
|
2012-06-29 |
2014-08-19 |
Ym Biosciences Australia Pty Ltd |
Phenyl amino pyrimidine bicyclic compounds and uses thereof
|
|
JOP20180012A1
(ar)
|
2012-08-07 |
2019-01-30 |
Janssen Pharmaceutica Nv |
عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
|
|
JP6359537B2
(ja)
|
2012-08-07 |
2018-07-18 |
ヤンセン ファーマシューティカ エヌ．ベー． |
複素環エステル誘導体の調製プロセス
|
|
CN102827085A
(zh)
*
|
2012-09-17 |
2012-12-19 |
符爱清 |
2,4,5-三氯嘧啶化合物的制备方法
|
|
TWI569799B
(zh)
|
2012-09-21 |
2017-02-11 |
安羅格製藥股份有限公司 |
抑制組成型活性磷酸化ｆｌｔ３激酶的方法
|
|
EP2903970A4
(en)
|
2012-10-08 |
2016-11-30 |
Portola Pharm Inc |
SUBSTITUTED PYRIMIDINYL KINASE INHIBITORS
|
|
BR112015016282A2
(pt)
|
2013-01-07 |
2017-07-11 |
Arog Pharmaceuticals Inc |
crenolanibe para tratamento de distúrbios proliferativos de flt3 mutado
|
|
WO2014159690A1
(en)
|
2013-03-12 |
2014-10-02 |
Vertex Pharmaceuticals Incorporated |
Dna-pk inhibitors
|
|
PL3424920T3
(pl)
|
2013-10-17 |
2020-11-16 |
Vertex Pharmaceuticals Incorporated |
Kokryształy (S)-N-metylo-8-(1-((2'-metylo-4’,6'-dideutero-[4,5'-bipirymidyn]-6-ylo)amino)propan-2-ylo)chinolino-4-karboksyamidu i ich deuterowane pochodne jako inhibitory DNA-PK
|
|
US10463658B2
(en)
|
2013-10-25 |
2019-11-05 |
Videra Pharmaceuticals, Llc |
Method of inhibiting FLT3 kinase
|
|
KR101910720B1
(ko)
*
|
2013-11-01 |
2018-10-22 |
노파르티스 아게 |
키나제 억제제로서의 아미노헤테로아릴 벤즈아미드
|
|
AU2014361798B2
(en)
|
2013-12-13 |
2020-06-11 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
US9908872B2
(en)
|
2013-12-13 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
Methods to treat lymphoplasmacytic lymphoma
|
|
TW202134236A
(zh)
|
2014-06-12 |
2021-09-16 |
美商西爾拉癌症醫學公司 |
N-(氰基甲基)-4-(2-(4-𠰌啉基苯基胺基)嘧啶-4-基)苯甲醯胺
|
|
BR112017002001B1
(pt)
|
2014-07-31 |
2022-10-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Compostos e composição farmacêutica
|
|
EP3193904B1
(en)
*
|
2014-08-18 |
2025-10-01 |
Cornell University |
Dipeptidomimetics as inhibitors of human immunoproteasomes
|
|
EP3715346B1
(en)
|
2014-10-22 |
2024-01-03 |
Dana-Farber Cancer Institute, Inc. |
Thiazolyl-containing compounds for treating proliferative diseases
|
|
US10227328B2
(en)
*
|
2015-02-04 |
2019-03-12 |
Beyondbio Inc. |
Heterocyclic compound and pharmaceutical composition comprising same
|
|
ES2899906T3
(es)
|
2015-07-06 |
2022-03-15 |
Alkermes Inc |
Inhibidores bicíclicos de histona desacetilasa
|
|
EP3319968A1
(en)
|
2015-07-06 |
2018-05-16 |
Rodin Therapeutics, Inc. |
Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
|
|
EP3254698A1
(en)
|
2016-06-08 |
2017-12-13 |
Universite De Montpellier |
Flt3 receptor inhibitor at low dosage for the treatment of neuropathic pain
|
|
WO2018064092A1
(en)
|
2016-09-27 |
2018-04-05 |
Vertex Pharmaceuticals Incorporated |
Method for treating cancer using a combination of dna-damaging agents and dna-pk inhibitors
|
|
HK1257195A1
(zh)
|
2016-11-02 |
2019-10-18 |
安罗格制药有限责任公司 |
用於治疗flt3突变型增殖性疾患相关突变的克莱拉尼
|
|
ES2875562T3
(es)
|
2017-01-11 |
2021-11-10 |
Alkermes Inc |
Inhibidores bicíclicos de histona desacetilasa
|
|
IL270224B1
(en)
|
2017-05-02 |
2024-04-01 |
Novartis Ag |
Combination therapy employing trametinib and a defined raf inhibitor
|
|
WO2018211018A1
(en)
|
2017-05-17 |
2018-11-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Flt3 inhibitors for improving pain treatments by opioids
|
|
WO2018217766A1
(en)
|
2017-05-22 |
2018-11-29 |
Whitehead Institute For Biomedical Research |
Kcc2 expression enhancing compounds and uses thereof
|
|
US11225475B2
(en)
|
2017-08-07 |
2022-01-18 |
Alkermes, Inc. |
Substituted pyridines as inhibitors of histone deacetylase
|
|
WO2019057649A1
(en)
|
2017-09-19 |
2019-03-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
|
|
CN110833551B
(zh)
*
|
2018-08-15 |
2023-03-24 |
广西梧州制药（集团）股份有限公司 |
吡唑并嘧啶衍生物在治疗急性胰腺炎的用途
|
|
AU2019364336B2
(en)
|
2018-10-22 |
2023-11-16 |
Alumis Inc. |
TYK2 inhibitors and uses thereof
|
|
US12208098B2
(en)
|
2018-11-26 |
2025-01-28 |
Gachon University Of Industry-Academic Cooperation Foundation |
4-carbonylamino-4-phenylpyrimidine compound or pharmaceutically acceptable salt thereof
|
|
JP2022520671A
(ja)
|
2019-02-08 |
2022-03-31 |
フリークエンシー・セラピューティクス・インコーポレイテッド |
耳障害を治療するためのバルプロ酸化合物及びｗｎｔ作動薬
|
|
EP4563150A3
(en)
|
2019-05-13 |
2025-07-23 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
|
|
WO2022019998A1
(en)
|
2020-07-20 |
2022-01-27 |
Arog Pharmaceuticals, Inc. |
Crystal forms of crenolanib and methods of use thereof
|
|
US11969420B2
(en)
|
2020-10-30 |
2024-04-30 |
Arog Pharmaceuticals, Inc. |
Combination therapy of crenolanib and apoptosis pathway agents for the treatment of proliferative disorders
|
|
WO2022090547A1
(en)
|
2020-10-30 |
2022-05-05 |
Dsm Ip Assets B.V. |
Production of carotenoids by fermentation
|
|
CN115677595B
(zh)
*
|
2022-10-26 |
2024-06-14 |
江苏睿实生物科技有限公司 |
一种2,4,5-三氯嘧啶的制备方法
|
|
CN116751191B
(zh)
*
|
2023-05-19 |
2025-09-16 |
凌科药业(杭州)有限公司 |
一种吡唑基-氨基-嘧啶基衍生物的晶型、制备方法及应用
|
|
KR20250075302A
(ko)
*
|
2023-11-21 |
2025-05-28 |
(주)신테카바이오 |
크레놀라닙 또는 이의 약학적으로 허용 가능한 염을 포함하는 아토피 피부염의 예방 또는 치료용 조성물
|